Trial Profile
The clinical study of Apatinib mesylate combined with Temozolomide in treating patients with recurrent high-grade glioma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2016
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 13 Dec 2016 New trial record